Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats

Research output: Contribution to journalJournal articlepeer-review

Standard

Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats. / Sommer, Jens Bak; Bach, Anders; Malá, Hana ; Strømgaard, Kristian; Mogensen, Jesper; Pickering, Darryl S.

In: Pharmacology, Biochemistry and Behavior, Vol. 161, 10.2017, p. 62-67.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Sommer, JB, Bach, A, Malá, H, Strømgaard, K, Mogensen, J & Pickering, DS 2017, 'Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats', Pharmacology, Biochemistry and Behavior, vol. 161, pp. 62-67. https://doi.org/10.1016/j.pbb.2017.09.008

APA

Sommer, J. B., Bach, A., Malá, H., Strømgaard, K., Mogensen, J., & Pickering, D. S. (2017). Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats. Pharmacology, Biochemistry and Behavior, 161, 62-67. https://doi.org/10.1016/j.pbb.2017.09.008

Vancouver

Sommer JB, Bach A, Malá H, Strømgaard K, Mogensen J, Pickering DS. Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats. Pharmacology, Biochemistry and Behavior. 2017 Oct;161:62-67. https://doi.org/10.1016/j.pbb.2017.09.008

Author

Sommer, Jens Bak ; Bach, Anders ; Malá, Hana ; Strømgaard, Kristian ; Mogensen, Jesper ; Pickering, Darryl S. / Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats. In: Pharmacology, Biochemistry and Behavior. 2017 ; Vol. 161. pp. 62-67.

Bibtex

@article{fe708c899fb14bb195d125237c4bf017,
title = "Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats",
abstract = "Pharmacological inhibition of PSD-95 is a promising therapeutic strategy in the treatment of stroke, and positive effects of monomeric and dimeric PSD-95 inhibitors have been reported in numerous studies. However, whether therapeutic effects will generalize to other types of acute brain injury such as traumatic brain injury (TBI), which has pathophysiological mechanisms in common with stroke, is currently uncertain. We have previously found a lack of neuroprotective effects of dimeric PSD-95 inhibitors in the controlled cortical impact model of TBI in rats. However, as no single animal model is currently able to mimic the complex and heterogeneous pathophysiology of TBI, it is necessary to assess treatment effects across a range of models. In this preliminary study we investigated the neuroprotective abilities of the dimeric PSD-95 inhibitor UCCB01-144 after fimbria-fornix (FF) transection in rats. UCCB01-144 or saline was injected into the lateral tail vein of rats immediately after sham surgery or FF-transection, and effects on spatial delayed alternation in a T-maze were assessed over a 28-day period. Task acquisition was significantly impaired in FF-transected animals, but there were no significant effects of UCCB01-144 on spatial delayed alternation after FF-transection or sham surgery, although decelerated learning curves were seen after treatment with UCCB01-144 in FF-transected animals. The results of the present study are consistent with previous research showing a lack of neuroprotective effects of PSD-95 inhibition in experimental models of TBI.",
author = "Sommer, {Jens Bak} and Anders Bach and Hana Mal{\'a} and Kristian Str{\o}mgaard and Jesper Mogensen and Pickering, {Darryl S}",
year = "2017",
month = oct,
doi = "10.1016/j.pbb.2017.09.008",
language = "English",
volume = "161",
pages = "62--67",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats

AU - Sommer, Jens Bak

AU - Bach, Anders

AU - Malá, Hana

AU - Strømgaard, Kristian

AU - Mogensen, Jesper

AU - Pickering, Darryl S

PY - 2017/10

Y1 - 2017/10

N2 - Pharmacological inhibition of PSD-95 is a promising therapeutic strategy in the treatment of stroke, and positive effects of monomeric and dimeric PSD-95 inhibitors have been reported in numerous studies. However, whether therapeutic effects will generalize to other types of acute brain injury such as traumatic brain injury (TBI), which has pathophysiological mechanisms in common with stroke, is currently uncertain. We have previously found a lack of neuroprotective effects of dimeric PSD-95 inhibitors in the controlled cortical impact model of TBI in rats. However, as no single animal model is currently able to mimic the complex and heterogeneous pathophysiology of TBI, it is necessary to assess treatment effects across a range of models. In this preliminary study we investigated the neuroprotective abilities of the dimeric PSD-95 inhibitor UCCB01-144 after fimbria-fornix (FF) transection in rats. UCCB01-144 or saline was injected into the lateral tail vein of rats immediately after sham surgery or FF-transection, and effects on spatial delayed alternation in a T-maze were assessed over a 28-day period. Task acquisition was significantly impaired in FF-transected animals, but there were no significant effects of UCCB01-144 on spatial delayed alternation after FF-transection or sham surgery, although decelerated learning curves were seen after treatment with UCCB01-144 in FF-transected animals. The results of the present study are consistent with previous research showing a lack of neuroprotective effects of PSD-95 inhibition in experimental models of TBI.

AB - Pharmacological inhibition of PSD-95 is a promising therapeutic strategy in the treatment of stroke, and positive effects of monomeric and dimeric PSD-95 inhibitors have been reported in numerous studies. However, whether therapeutic effects will generalize to other types of acute brain injury such as traumatic brain injury (TBI), which has pathophysiological mechanisms in common with stroke, is currently uncertain. We have previously found a lack of neuroprotective effects of dimeric PSD-95 inhibitors in the controlled cortical impact model of TBI in rats. However, as no single animal model is currently able to mimic the complex and heterogeneous pathophysiology of TBI, it is necessary to assess treatment effects across a range of models. In this preliminary study we investigated the neuroprotective abilities of the dimeric PSD-95 inhibitor UCCB01-144 after fimbria-fornix (FF) transection in rats. UCCB01-144 or saline was injected into the lateral tail vein of rats immediately after sham surgery or FF-transection, and effects on spatial delayed alternation in a T-maze were assessed over a 28-day period. Task acquisition was significantly impaired in FF-transected animals, but there were no significant effects of UCCB01-144 on spatial delayed alternation after FF-transection or sham surgery, although decelerated learning curves were seen after treatment with UCCB01-144 in FF-transected animals. The results of the present study are consistent with previous research showing a lack of neuroprotective effects of PSD-95 inhibition in experimental models of TBI.

U2 - 10.1016/j.pbb.2017.09.008

DO - 10.1016/j.pbb.2017.09.008

M3 - Journal article

C2 - 28943199

VL - 161

SP - 62

EP - 67

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

ER -

ID: 183476285